Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451481 | 1.00 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL10860800 | 1.00 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL2636857 | 0.90 | SMN1; SMN2 (0.35) | LMNASMN1; SMN2PGD | |
| SCHEMBL22288952 | 0.85 | PRKCA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL2386147 | 0.85 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL9274693 | 0.85 | PRKCA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL5198986 | 0.85 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL5452684 | 0.84 | LMNA (0.32) | LMNASMN1; SMN2PGD | |
| SCHEMBL13906596 | 0.84 | LMNA (0.35) | LMNASMN1; SMN2PGD | |
| SCHEMBL7530642 | 0.84 | LMNA (0.32) | LMNASMN1; SMN2PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341054-B1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS (SI) | 2014-06-25 | — | — | EP | disclosed |
| EP-1937696-B1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS (SI) | 2013-05-22 | — | — | EP | disclosed |
| US-8269001-B2 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2012-09-18 | — | — | US | disclosed |
| EP-2341054-A1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK Pharmaceuticals d.d. (SI) | 2011-07-06 | — | — | EP | disclosed |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-04 | — | — | US | disclosed |
| EP-1937696-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK Pharmaceuticals D.D. (SI) | 2008-07-02 | — | — | EP | disclosed |
| EP-1775299-A1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK Pharmaceuticals D.D. (SI) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007039287-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | HMGCR, COASY, LSS | LMNA 281/4885SMN1; SMN2 4399/4885PGD 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.